Adagio Therapeutics Announces New Data Highlighting ‘the Potential of ADG20 for Treatment and Prevention of COVID-19’
ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study
Data from Quantitative Systems